申请人:NOVO NORDISK A/S
公开号:EP0315959A2
公开(公告)日:1989-05-17
Heterocyclic dihydroxyquinoxaline compounds having the formula
wherein
R¹ is C₁₋₁₂-alkyl, which may obtionally be substituted by hydroxy, formyl, carboxy, carboxylic esters, amides or amines, C₃₋₈-cycloalkyl, aryl, aralkyl; and wherein R⁶ is, hydrogen, halogen, CN, CF₃, NO₂, or OR′, wherein R′ is C₁₋₄-alkyl and R⁵, R⁷ and R⁸ is hydrogen, provided R⁶ is not CF₃, OCH₃, NO₂, CL or Br when R¹ is CH₃; or
R⁶ and R⁷ independently are NO₂, halogen, CN, CF₃, or OR′, wherein R′ is C₁₋₄-alkyl, and R⁵ and R⁸ are each hydrogen; or
R⁵ and R⁶ together form a further fused aromatic ring, which may be substituted with halogen, NO₂, CN, CF₃ or OR′, wherein R′ is C₁₋₄-alkyl, and R⁷ and R⁸ independently are hydrogen, halogen, CN, CF₃, NO₂ or OR′ wherein R′ is C₁₋₄-alkyl; or
R⁷ and R⁸ together form a further fused aromatic ring, which may be substituted with halogen, NO₂, CN, CF₃ or OR′, wherein R′ is C₁₋₄-alkyl, and R⁵ and R⁶ independently are hydrogen, halogen, CN, CF₃, NO₂ or OR′, wherein R′ is C₁₋₄-alkyl.
The invention also relates to a method of preparing the compounds, pharmaceutical compositions thereof, and their use.
The compounds are useful in the treatment of indications caused by hyperactivity of the excitatory neurotransmitters, particularly the quisqualate receptors, and especially as neuroleptics.
具有以下式子的杂环二羟基喹喔啉化合物
其中
R¹ 是 C₁₋₁₂-烷基,可被羟基、甲酰基、羧基、羧酸酯、酰胺或胺、C₃₋₈-环烷基、芳基、芳烷基取代;其中 R⁶ 是氢、卤素、CN、CF₃、NO₂ 或 OR′,其中 R′ 是 C₁₋₄-烷基和 R⁵、R⁷ 和 R⁸ 是氢,条件是 R⁶ 不是 CF₃、OCH₃、NO₂、CL 或 Br(当 R¹ 是 CH₃ 时);或
R⁶ 和 R⁷ 独立地为 NO₂、卤素、CN、CF₃ 或 OR′,其中 R′为 C₁₋₄-烷基,且 R⁵ 和 R⁸ 均为氢;或
R⁵ 和 R⁶ 共同形成另一个可被卤素、NO₂、CN、CF₃ 或 OR′取代的融合芳环、其中 R′为 C₁₄-烷基,且 R⁷ 和 R⁸ 独立地为氢、卤素、CN、CF₃、NO₂ 或 OR′,其中 R′为 C₁₄-烷基;或
R⁷ 和 R⁸ 共同形成另一个可被卤素、NO₂、CN、CF₃ 或 OR′取代的融合芳环、其中 R′为 C₁₋₄-烷基,且 R⁵ 和 R⁶ 独立地为氢、卤素、CN、CF₃、NO₂ 或 OR′,其中 R′为 C₁₋₄-烷基。
本发明还涉及化合物的制备方法、其药物组合物及其用途。
本发明的化合物可用于治疗兴奋性神经递质,特别是喹乙醇受体亢进引起的适应症,尤其可用作神经抑制剂。